0RFI.LSE BRAIN Biotech AG
- Market cap
- EUR 46.1M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0RFI.LSE undervalued?
Graham numberThe Graham number of BRAIN Biotech AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BRAIN Biotech AG fundamental analysis
No fundamental analysis for BRAIN Biotech AG yet.
BRAIN Biotech AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. …
Full company profileFinancial statements of BRAIN Biotech AG are not available yet.
BRAIN Biotech AG dividends
BRAIN Biotech AG has not paid dividends in the last 4 fiscal years.
Who owns BRAIN Biotech AG
- Insiders 58.40%
- Institutions 8.48%
- Public & others 33.12%
- Shares outstanding 18.1M
- Free float 9.09M
BRAIN Biotech AG company profile
- Company name
- BRAIN Biotech AG
- Ticker
- 0RFI.LSE
- ISIN
- DE0005203947
- Exchange
- London Exchange
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Employees
- 280
- Fiscal year end
- September
- Address
- DarmstAedter Strasse 34-36, Zwingenberg, Germany, 64673
- Phone
- 49 62 51 9331 0
- Website
- brain-biotech.com
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
BRAIN Biotech AG management
9- Dr. Sven K. WeberCEO & Chairman of the Executive Board · born 1982
- Mr. Ulrich PutschCo-Founder
- Mr. Michael SchneidersCFO & Member of Management Board · born 1970
- Dr. Ute DechertVice President of Human Resources & Processes · born 1961
- Dr. Jurgen EckConsultant · born 1962
- Dr. Martin LangerMD & Executive VP · born 1965
- Dr. Alexander PelzerVP and Head of Research & Development - Zwingenberg · born 1986
- Mr. Robbert Michael HoekstraHead of Group Finance · born 1978
- Mr. Johan Jansen-StorbackaExecutive VP of BRAIN Biocatalysts enzyme products business